Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Can-Fite BioPharma (CANF)
NYSE MKT:CANF
Holding CANF?
Track your performance easily
CANF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.87 - $4.69
Previous Close$2.01
Volume11.31K
Average Volume (3M)99.13K
Market Cap
$14.76M
Enterprise Value$5.88M
Total Cash (Recent Filing)$8.92M
Total Debt (Recent Filing)$40.00K
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Nov 29, 2024EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding5,570,000
10 Day Avg. Volume70,996
30 Day Avg. Volume99,126
Standard Deviation0.19
R-Squared0.15
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)1.79
Price to Sales (P/S)72.95
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.41
Enterprise Value/Gross Profit7.92
Enterprise Value/Ebitda-1.27
Forecast
1Y Price Target
$18.00Price Target Upside795.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Can-Fite BioPharma News
PremiumCompany Announcements
Can-Fite BioPharma Advances in Pancreatic Cancer Trial
PremiumCompany Announcements
Can-Fite BioPharma Secures Australian Patent for Obesity Drug
PremiumCompany Announcements
Can-Fite BioPharma Secures Lucrative Deal with Vetbiolix
PremiumCompany Announcements
Can-Fite’s Namodenoson Gains FDA Orphan Status
Ownership Overview
―
Insiders
―
Mutual Funds
9.54% Other Institutional Investors
90.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CANF FAQ
What was Can-Fite BioPharma’s price range in the past 12 months?
Can-Fite BioPharma lowest stock price was $1.87 and its highest was $4.69 in the past 12 months.
What is Can-Fite BioPharma’s market cap?
Currently, no data Available
When is Can-Fite BioPharma’s upcoming earnings report date?
Can-Fite BioPharma’s upcoming earnings report date is Nov 29, 2024 which is in 8 days.
How were Can-Fite BioPharma’s earnings last quarter?
Can-Fite BioPharma released its earnings results on Aug 29, 2024. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.22.
Is Can-Fite BioPharma overvalued?
According to Wall Street analysts Can-Fite BioPharma’s price is currently Undervalued.
Does Can-Fite BioPharma pay dividends?
Can-Fite BioPharma does not currently pay dividends.
What is Can-Fite BioPharma’s EPS estimate?
Can-Fite BioPharma’s EPS estimate is -$0.27.
How many shares outstanding does Can-Fite BioPharma have?
Can-Fite BioPharma has 6,813,572 shares outstanding.
What happened to Can-Fite BioPharma’s price movement after its last earnings report?
Can-Fite BioPharma reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went down -2.597%.
Which hedge fund is a major shareholder of Can-Fite BioPharma?
Currently, no hedge funds are holding shares in CANF
---
Can-Fite BioPharma Stock Smart Score
Company Description
Can-Fite BioPharma
Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical company, which focuses on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological and ophthalmic diseases. Its products include pipeline drugs such as CF101, CF102 and CF602. The company offers drugs for the treatment of Psoriasis, Rheumatic Arthritis, Glaucoma, Uveitis, Crohn's disease, Osteoathritis, Hepatitis C, and Liver Cancer. Can-Fite BioPharma was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach Tikva, Israel.
---
CANF Stock 12 Month Forecast
Average Price Target
$18.00
▲(795.52% Upside)
Technical Analysis
Best Analysts Covering CANF
1 Year
1 Year Success Rate
4/34 ratings generated profit
1 Year Average Return
-42.79%
initiated a buy rating 4 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 11.76% of your transactions generating a profit, with an average return of -42.79% per trade.
---